Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACH-126, 443 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ACH-126,443 | DRUG | - |
| Lamivudine | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Chronic hepatitis B virus (HBV) infection, known to be hepatitis B surface antigen positive ≥ 6 months. * Plasma HBV deoxyribonucleic acid level ≥ 100,000 copies/milliliter. * Hepatitis B e-antigen positive. * Human immunodeficiency virus negative. * Basic hematologic and chem...
ACH-126,443 is an investigational small molecule being studied for the treatment of chronic hepatitis B. It was evaluated in a Phase 2 clinical trial in treatment-naive adults with chronic hepatitis B virus infection. The drug is not approved and remains in clinical development.
ACH-126,443 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker AZN. The company conducted a Phase 2 clinical trial of the drug in patients with chronic hepatitis B.
ACH-126,443 is in Phase 2 clinical development. A Phase 2 study of the drug has been completed, but it is not approved and is still investigational. The completed trial enrolled 79 participants with chronic hepatitis B.
ACH-126,443 has one completed clinical trial, registered as NCT00034359. This Phase 2 study assessed the safety and antiviral activity of ACH-126,443 in treatment-naive adults with chronic hepatitis B virus infection. The trial enrolled 79 participants and was conducted in Bulgaria and the Federal Republic of Yugoslavia.
ACH-126,443 is also known as beta-L-Fd4C. The clinical trial NCT00034359 evaluated ACH-126,443 (beta-L-Fd4C) in patients with chronic hepatitis B. Both names refer to the same investigational drug.